Clinical trials: Ischemic Stroke, Acute
- Condition Ischemic Stroke, Acute
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke
Millipede AspiRation for Revascularization in Stroke (MARRS) Study
The objectives of the study are to examine the performance and safety characteristics of the Millipede System when used for revascularization of patients with acute ischemic stroke due to Large Vessel Occlusions (LVOs) and to…
- Trial name
- MARRS (NCT05714501)
- Testing
- Millipede System
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 235 people
- Sponsor
- Perfuze
Acute Ischemic Stroke From Large Vessel Occlusion
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (2.5mm or greater in diameter) occlusion…
- Trial name
- NCT01584609
- Testing
- Penumbra System with Separator 3D, Penumbra System alone
- Where
- 8 sites in United States
- Volunteers
- 198 people
- Sponsor
- Penumbra Inc.
Ischemic Stroke
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke…
- Trial name
- EPICA (NCT02793687)
- Testing
- Mexidol
- Where
- 11 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living.
- Trial name
- ACTION2 (NCT02730455)
- Testing
- natalizumab
- Where
- 53 sites in United States, Germany and 2 more
- Volunteers
- 277 people
- Sponsor
- Biogen
Acute Ischemic Stroke, Large Vessel Occlusion
THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing
The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to…
- Trial name
- NCT05437055
- Testing
- Mechanical Thrombectomy (Penumbra System with Thunderbolt)
- Where
- 32 sites in United States
- Volunteers
- 216 people
- Sponsor
- Penumbra Inc.
Stroke
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
The purpose of this study is: To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS-LED (NCT00938314)
- Testing
- human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Stem Cell Therapeutics Corp.
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Stroke
Study to Assess the Safety and Effectiveness of the Penumbra System
This clinical evaluation is a prospective, single-arm, multi-center trial. The purpose of this clinical evaluation is to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting…
- Trial name
- NCT00334061
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Penumbra Inc.
Stroke, Acute, Neurological Impairment
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.
- Trial name
- NCT00276380
- Testing
- EGb761, Acetylsalicylic acid
- Where
- 10 sites in Czechia, Poland and 2 more
- Volunteers
- 204 people
- Sponsor
- Ipsen
Acute Ischemic Stroke
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment.
- Trial name
- EAISE (NCT04309474)
- Testing
- Elezanumab
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 121 people
- Sponsor
- AbbVie
Ischemic Stroke
Efficacy and Safety of Mexidol® in Stroke Therapy
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo.
- Trial name
- MIR (NCT06437626)
- Testing
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Where
- 17 sites in Kazakhstan, Russia and 1 more
- Volunteers
- 304 people
- Sponsor
- Pharmasoft
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Acute Ischemic Stroke (AIS)
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological…
- Trial name
- NCT00821821
- Testing
- MCI-186
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 36 people
- Sponsor
- Shionogi
Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Trial name
- NCT04091945
- Testing
- LT3001 Drug Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 24 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Ischemic Stroke, Acute, Brain Diseases
Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke
- Conditions
- Ischemic Stroke, Acute, Brain Diseases, Cerebrovascular Disorders
- Trial name
- NCT04973332
- Testing
- Intracranial thrombectomy stent
- Where
- 14 sites in China
- Volunteers
- 218 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Atrial Fibrillation
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in…
- Trial name
- NCT03258645
- Testing
- Dabigatran
- Where
- Sweden
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)
The main objective of this study is to document that the thrombectomy catheter (Rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are…
- Trial name
- NCT01895634
- Testing
- Rev-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb